• Login
  • Register
The Daily Sceptic
No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Podcasts
  • Newsletter
  • Premium
  • Donate
  • Log In
The Daily Sceptic
No Result
View All Result

Ivermectin: Cheap Covid Treatment Shown to be Highly Effective in New Peer-Reviewed Study

by Will Jones
3 May 2021 10:38 PM

A new peer-reviewed study by Dr Pierre Kory and colleagues on Ivermectin has been published in the American Journal of Therapeutics. Entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19“, it provides a new authoritative overview of the evidence to date and calls for the widely available drug to be “globally and systematically deployed in the prevention and treatment of COVID-19”.

The study summarises the impressive evidence base for the use of Ivermectin.

1. Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue, and others.
2. Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue through several observed and proposed mechanisms.
3. Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation.
4. Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses.
5. Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients.
6. Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms.
7. Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalised patients.
8. Ivermectin reduces mortality in critically ill patients with COVID-19.
9. Ivermectin leads to temporally associated reductions in case fatality rates in regions after ivermectin distribution campaigns.
10. The safety, availability, and cost of ivermectin are nearly unparalleled given its low incidence of important drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered.
11. The World Health Organisation has long included ivermectin on its “List of Essential Medicines.”

The quality of the evidence for Ivermectin has been challenged, leading many countries including the U.K. and U.S. not to recommend its use for COVID-19. The study takes this criticism head-on.

Although a subset of trials are of an observational design, it must be recognised that in the case of ivermectin (1) half of the trials used a randomised controlled trial design (12 of the 24 reviewed above) and (2) observational and randomised trial designs reach equivalent conclusions on average as reported in a large Cochrane review of the topic from 2014. In particular, OCTs that use propensity-matching techniques (as in the Rajter study from Florida) find near identical conclusions to later-conducted RCTs in many different disease states, including coronary syndromes, critical illness, and surgery. Similarly, as evidenced in the prophylaxis and treatment trial meta-analyses as well as the summary trials table, the entirety of the benefits found in both OCT and RCT trial designs aligns in both direction and magnitude of benefit. Such a consistency of benefit among numerous trials of varying sizes designs from multiple different countries and centres around the world is unique and provides strong, additional support.

A hint of the politics around Ivermectin can be gleaned in the discussion section, where the authors wonder how much more evidence a cheap, safe drug like Ivermectin needs in an international emergency before it can be approved.

The continued challenges faced by health care providers in deciding on appropriate therapeutic interventions in patients with COVID-19 would be greatly eased if more updated and commensurate evidence-based guidance came from the leading governmental health care agencies. Currently, in the United States, the treatment guidelines for COVID-19 are issued by the National Institutes of Health. Their most recent recommendation on the use of ivermectin in patients with COVID-19 was last updated on February 11th, 2021, where they found that “there was insufficient evidence to recommend for or against ivermectin in COVID-19”. For a more definitive recommendation to be issued by major leading public health agencies (PHA), it is apparent that even more data on both the quality and quantity of trials are needed, even during a global health care emergency, and in consideration of a safe, oral, low-cost, widely available and deployable intervention such as ivermectin.

The authors add that further evidence is on its way and express an earnest hope that “if the above benefits in clinical outcomes continue to be reported in the remaining trials … this almost doubling of the current supportive evidence base would merit a recommendation for use by the WHO, NIH, and other PHAs”.

The study includes two striking graphs, from Peru and Uruguay, illustrating the strong association of Ivermectin use with reduction in Covid infections and deaths.

Alto Parana used Ivermectin from where the line goes bold whereas the other states did not
In Peru, Lima did not use Ivermectin whereas the other states did

Considering how quickly vaccines using novel technology with unproven long-term safety records have been authorised for use, the failure to approve a known safe drug with considerable evidence to suggest clinical benefit is almost inexplicable. Some have suggested the resistance has been motivated by a wish among pharmaceutical companies to prioritise more profitable medicines like the vaccines. If so, this is a criminal example of putting profits before people.

It is good to see this study make it to publication. (There are rumours that some journals rejected it, not for any technical reason but because it would be controversial, possibly with their sponsors.) It is to be hoped there will be many more such studies, and a sea-change in regulators’ attitudes to repurposed medicines like Ivermectin.

Tags: IvermectinTreatments

Donate

We depend on your donations to keep this site going. Please give what you can.

Donate Today

Comment on this Article

You’ll need to set up an account to comment if you don’t already have one. We ask for a minimum donation of £5 if you'd like to make a comment or post in our Forums.

Sign Up
Previous Post

Britain Records One Covid Death in Lowest Daily Toll in Nine Months – Yet Boris Doggedly Sticks to Roadmap

Next Post

News Round Up

Subscribe
Login
Notify of
Please log in to comment

To join in with the discussion please make a donation to The Daily Sceptic.

Profanity and abuse will be removed and may lead to a permanent ban.

93 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
emel
emel
2 years ago

Actually, life is just a bowl of All Bran, to quote the song.

Last edited 2 years ago by emel
17
-1
stewart
stewart
2 years ago

Indeed. What’s so offensive about asking whether a person is from Africa?

What could be more racist than thinking that coming from Africa is insulting?

70
-2
Jon Mors
Jon Mors
2 years ago

I’m half British and have spent my adult life here. I identify as British, as least in part. I don’t care much for the character traits of the people with which I share my other nationality.

I’ve had people say I don’t have an accent, but sometimes at least I must do, as I occassionally do get asked where I am from. This does annoy me, as I feel it casts me as an outsider.

Also, it hurts my pride a bit, as I like to think my upper crust accent is near perfect.

I do realise that people think it is polite to show an interest, which to a point it is. What I would say is that this Lady whatshername should have realised that when the black lady with the African clothes said she was from Hackney, that was a massive hint to move on to the next conversation topic.

15
-22
RTSC
RTSC
2 years ago
Reply to  Jon Mors

That would have been the right response IF the woman in question wasn’t wearing African Fancy Dress and was clearly signalling her ethnic origins and therefore inviting a question about her origins.

It was a set-up.

38
0
RTSC
RTSC
2 years ago

I was shopping in Wells market a couple of weeks ago and a chap running a stall spoke English with a strong accent so I asked him where he came from. I was interested in his background – I wanted to learn something. He seemed happy to chat and it turned out he was Romanian. I asked him about Bucherest and how I’d get from there to Transylvania to “Dracula’s castle.” He gave me some advice.

It was a perfectly civilised, interesting conversation. I wasn’t rude and neither was he. I bought something from him.

The British-born woman who chose to wear African Fancy Dress to the Palace was on a mission to “make a point and be offended” and unfortunately, Lady Hussey didn’t understand that so walked into the trap.

Charlie-boy and William’s reaction was disgraceful.

54
0
7941MHKB
7941MHKB
2 years ago
Reply to  RTSC

I have also read that the “African” lady has parents from Barbados and a birth name to match.

Fair enough, but wouldn’t that make her guilty of “Cultural Misappropriation”, at least as bad as some youth wearing a sombrero in a Mexican restaurant?

And strange that she and her chum managed to have the event on film?

A shame a curious 83 year old should have 62 years of service to the Crown vaporised, by the King and her Godson Prince. They should (but won’t be) thoroughly ashamed.

41
0

NEWSLETTER

View today’s newsletter

To receive our latest news in the form of a daily email, enter your details here:

DONATE

PODCAST

In Episode 35 of the Sceptic: Andrew Doyle on Labour’s Grooming Gang Shame, Andrew Orlowski on the India-UK Trade Deal and Canada’s Ignored Covid Vaccine Injuries

by Richard Eldred
9 May 2025
1

LISTED ARTICLES

  • Trending
  • Comments
  • Latest

Sun-Dimming Quango has £800 Million of Taxpayer Money to Blow – and a CEO on £450k

8 May 2025

News Round-Up

9 May 2025

The Sugar Tax Sums Up Our Descent into Technocratic Dystopia

8 May 2025

UK “Shafted” by US Trade Deal

8 May 2025

What Does David Lammy Mean by a State?

9 May 2025

News Round-Up

26

The Sugar Tax Sums Up Our Descent into Technocratic Dystopia

25

Sun-Dimming Quango has £800 Million of Taxpayer Money to Blow – and a CEO on £450k

28

Electric Car Bursts into Flames on Driveway and Engulfs £550,000 Family Home

11

What Does David Lammy Mean by a State?

11

BBC Quietly Edits Question Time After Wrongly ‘Correcting’ Richard Tice on Key Net Zero Claim

9 May 2025

Electric Car Bursts into Flames on Driveway and Engulfs £550,000 Family Home

9 May 2025

“I Was a Super Fit Cyclist Until I Had the Moderna Covid Vaccine. What Happened Next Left Me Wishing I Was Dead”

9 May 2025

Nature Paper Claims to Pin Liability for ‘Climate Damages’ on Oil Companies

9 May 2025

What Does David Lammy Mean by a State?

9 May 2025

POSTS BY DATE

May 2021
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
« Apr   Jun »

SOCIAL LINKS

Free Speech Union
  • Home
  • About us
  • Donate
  • Privacy Policy

Facebook

  • X

Instagram

RSS

Subscribe to our newsletter

© Skeptics Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
wpDiscuz
No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Podcasts
  • Newsletter
  • Premium
  • Donate
  • Log In

© Skeptics Ltd.

You are going to send email to

Move Comment
Perfecty
Do you wish to receive notifications of new articles?
Notifications preferences